BHCM
DNTH icon

Brevan Howard Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Brevan Howard Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.63M Sell
19,430
-32,270
-62% -$1.87M 0.01% 655
2025
Q4 		$2.14M Buy
51,700
+39,770
+333% +$1.54M 0.02% 467
2025
Q3 		$469K Buy
+11,930
New +$305K ﹤0.01% 1324
2024
Q2 		– Sell
-12,253
Closed -$368K – 1128
2024
Q1 		$368K Buy
+12,253
New +$266K ﹤0.01% 572

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Brevan Howard Capital Management's DNTH Position: Q1 2026 in Review

Brevan Howard Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 62% in Q1 2026, selling an estimated $1.87M and leaving 19,430 shares worth $1.63M. The position accounts for 0.01% of the portfolio, ranked #655.

Brevan Howard Capital Management first reported a position in DNTH in Q1 2024 and has held it in 4 quarters since. The position peaked at $2.14M in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Brevan Howard Capital Management held 19,430 shares of Dianthus Therapeutics worth $1.63M as of Q1 2026.
  • Brevan Howard Capital Management sold 32,270 Dianthus Therapeutics shares in Q1 2026, an estimated $1.87M.
  • Dianthus Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #655 holding.
  • Brevan Howard Capital Management first reported a position in Dianthus Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • Brevan Howard Capital Management's Dianthus Therapeutics position peaked at $2.14M in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.